On the morning of March 30, our chairman Shi Yuanyuan, chief scientist Wang Jianxun, Director of Sales Yang Bolui, Assistant Director Wei Zheng and Deputy Director of Research and Development Sun Rui went to Suzhou Fangde Menda New Drug Development Co., LTD. (hereinafter referred to as "Fangde Menda") for a visit and exchange. Li Jun, founder and CEO of Fangde Menda, Liu Kaichun, head of research and development, and Ji Chenxia, assistant general manager of Fangde Menda warmly received and held a symposium.

At this meeting, the team of Shenzhen Cell Valley and Fangde Menda respectively introduced the company's development, core team, R&D and production pipeline, core technology advantages and other aspects in detail, and discussed the future cooperation model. Fande Menda is a high-tech enterprise focusing on the research and development of innovative drugs. The successful development of This CAR-T universal CAR-T platform technology, which adopts the membrane protein intracellular retention technology with independent intellectual property rights, not only fundamentally avoids the off-target risk of gene editing, but also the preparation process is almost completely consistent with autologous CAR-T (" second change "). The expression of CAR and the elimination of GvHD can be achieved simultaneously by using a single virus vector.

Dr. Li Jun said that its universal CAR-T version 2.0 plans to use retrovirus vectors from Shenzhen Cell Valley to create a new form of universal CAR-T. Shenzhen Cell Valley has accumulated rich experience in the industrial production of retroviral vectors, and has a professional R & D team and a complete set of technological solutions, which can provide a series of services from retroviral vector design and transformation, viral vector preparation to cell production and preparation.